Liraglutide Medicaid Coverage by State Tier (2026 Guide)

What Is Liraglutide and Why Does Tier Placement Matter?

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. The FDA approved Victoza (liraglutide 1.2 mg and 1.8 mg) in January 2010 for glycemic control in adults with type 2 diabetes and, later, for cardiovascular risk reduction in adults with established cardiovascular disease [1]. Saxenda (liraglutide 3.0 mg) received FDA approval in December 2014 for chronic weight management in adults with a BMI of 30 or higher, or BMI <27 with at least one weight-related comorbidity [2].

Medicaid formulary tier placement determines how much you pay and what hoops you must clear before a prescription is filled. A drug placed on Tier 1 (preferred generic) costs pennies; a drug placed on Tier 4 or Specialty can require prior authorization (PA), step therapy, and a copay that can exceed $100 per month even with coverage. Because liraglutide has no FDA-approved generic as of January 2026, every state places it on a non-preferred brand or specialty tier [3].

How Medicaid Formulary Tiers Work

Most state Medicaid programs use a three-to-five tier structure. Tier 1 holds preferred generics, Tier 2 holds preferred brands, Tier 3 covers non-preferred brands, and Tier 4 or a separate "Specialty" tier covers high-cost biologics and branded injectables. Liraglutide almost always lands on Tier 3 or Specialty. The practical consequence: without a successful PA, the pharmacy will reject the claim.

The Federal Floor for Medicaid Drug Coverage

Federal law does not require state Medicaid programs to cover every FDA-approved drug. States receive a mandatory rebate from manufacturers under the Medicaid Drug Rebate Program (MDRP), but coverage decisions remain a state prerogative [4]. The Centers for Medicare and Medicaid Services (CMS) guidance allows states to exclude obesity medications entirely, which explains why Saxenda coverage is patchy across state programs [5].

Victoza (Liraglutide for Diabetes): State Coverage Overview

Victoza coverage for type 2 diabetes is broader than Saxenda coverage because type 2 diabetes is an unambiguous chronic disease with established treatment pathways. The LEADER trial (N=9,340) showed liraglutide 1.8 mg reduced major adverse cardiovascular events by 13% versus placebo (HR 0.87, 95% CI 0.78-0.97, P<0.001 for non-inferiority and P=0.01 for superiority), which has driven guideline-based prescribing that many states have incorporated into PA criteria [6].

States With Preferred or Non-Restricted Coverage

A small number of states, including New York, California (Medi-Cal), and Illinois, cover Victoza on the non-preferred brand tier with PA but without mandatory step therapy beyond metformin. Prescribers in these states can obtain approval by documenting HbA1c above 7.5% and a 90-day trial of metformin (or intolerance to metformin).

States Requiring Multi-Drug Step Therapy

Texas, Florida, Georgia, and several other Southern states require documented failure of two or more oral antidiabetic agents (typically metformin plus a sulfonylurea) before approving Victoza. The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists as second-line agents in patients with established cardiovascular disease or high cardiovascular risk, regardless of HbA1c [7]. Citing this guideline explicitly in a PA letter strengthens the case for skipping step therapy.

States That Do Not Cover Victoza

A handful of states with tightly managed Medicaid formularies, including Wyoming and South Dakota, effectively exclude liraglutide by listing only metformin, sulfonylureas, and one DPP-4 inhibitor as covered antidiabetics. In these states, the prescriber may appeal by documenting medical necessity, but approval rates are low.

Saxenda (Liraglutide for Weight Management): Why Coverage Is So Restricted

Saxenda coverage is where the real access gap lives. Most state Medicaid programs historically excluded anti-obesity medications under a provision that traces back to federal guidance allowing exclusion of drugs "used for weight loss" [8]. As of early 2026, only approximately 12 to 15 states cover Saxenda under Medicaid, and nearly all require extensive documentation.

The CMS 2023 Proposed Rule and Its Impact

CMS published a proposed rule in late 2023 that would require Medicaid programs to cover FDA-approved anti-obesity medications, but finalization and implementation timelines remain in flux [9]. States are not yet required to comply, meaning coverage in 2026 still varies widely. Patients and prescribers should check their state's preferred drug list (PDL) directly, as policies may shift mid-year.

States That Cover Saxenda Under Medicaid (as of Early 2026)

The states most likely to cover Saxenda include California, Colorado, Michigan, Massachusetts, Minnesota, New Jersey, Oregon, Pennsylvania, Washington, and a small number of others that have voluntarily expanded anti-obesity drug coverage. Each program sets its own criteria, but common requirements include:

• BMI of 30 or higher (or BMI <27 with documented comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea)
• Documented enrollment in a behavioral weight management program for at least 90 days
• Prior failure of at least one other anti-obesity intervention
• Prescriber attestation that the patient has no contraindications (personal or family history of medullary thyroid carcinoma or MEN2, per the FDA boxed warning) [10]

Documentation That Speeds Approval

The SCALE Obesity and Prediabetes trial (N=3,731) showed liraglutide 3.0 mg produced 8.0% mean weight loss at 56 weeks versus 2.6% placebo (P<0.001) [11]. Quoting this trial outcome in a PA letter, alongside the patient's weight trajectory and comorbidity burden, provides objective clinical support. Attach recent labs (HbA1c, lipids, blood pressure readings) and the behavioral program enrollment record.

Prior Authorization: What Prescribers and Patients Must Submit

A PA for liraglutide typically requires four categories of documentation: diagnosis confirmation, step therapy evidence, clinical metrics, and prescriber attestation. Missing even one element is the most common reason for first-round denial.

Required Documentation Checklist

1. Diagnosis code. E11.x for type 2 diabetes (Victoza) or E66.x for obesity (Saxenda). Submitting the wrong ICD-10 code is an automatic denial.
2. Step therapy records. Pharmacy fill history or chart notes documenting prior drug trials with dates, doses, and reason for discontinuation.
3. Clinical metrics. Most recent HbA1c (for Victoza) or BMI with weight history (for Saxenda), dated within 90 days.
4. Prescriber attestation. A signed statement confirming the absence of contraindications and the medical necessity of liraglutide specifically.
5. Behavioral program enrollment (Saxenda only in most states). Letter of enrollment or attendance record.

Appeal Strategies When PA Is Denied

First-level appeals succeed approximately 30 to 40% of the time when new clinical evidence is added. The most effective additions are a letter of medical necessity from a specialist (endocrinologist or cardiologist for Victoza; bariatric medicine specialist for Saxenda), a published guideline citation, and patient-specific risk quantification. The ADA position statement on anti-obesity pharmacotherapy supports GLP-1 use as first-line pharmacotherapy in patients with obesity and type 2 diabetes [12]. A second-level appeal, or an external appeal to an independent review organization, is available in every state under the ACA.

How to Get Liraglutide Cheaper: Every Cost-Reduction Path

Even with coverage, liraglutide can carry significant out-of-pocket costs. Without insurance, Saxenda lists near $1,400 per month and Victoza near $900 per month. Several legitimate paths can cut those numbers substantially.

Novo Nordisk Patient Assistance and Copay Programs

Novo Nordisk runs the "Novo Nordisk Patient Assistance Program" for uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). Eligible patients may receive Victoza or Saxenda at no cost [13]. The manufacturer copay card, "My$99Insulin" equivalent programs for GLP-1s, applies only to commercially insured patients and cannot be used with any federal program including Medicaid or Medicare.

GoodRx and Third-Party Discount Cards

GoodRx and similar discount platforms negotiate prices with pharmacy benefit managers. A GoodRx coupon for liraglutide 1.8 mg (one pen, 18 mg/3 mL) can reduce the retail price by 20 to 40% at major chains. These discounts cannot be combined with Medicaid or Medicare Part D, but they are legal for cash-pay patients or those in the coverage gap.

HSA and FSA Eligibility

Both Victoza and Saxenda are eligible for purchase with Health Savings Account (HSA) or Flexible Spending Account (FSA) funds when a licensed prescriber has issued a valid prescription [14]. The IRS defines qualified medical expenses to include prescription drugs, making liraglutide fully HSA/FSA-eligible. Patients on high-deductible health plans who have not yet met their deductible can use pre-tax HSA dollars to pay for liraglutide, effectively reducing the after-tax cost by their marginal income tax rate.

340B Program Pharmacies

Federally qualified health centers (FQHCs), rural health clinics, and certain hospital outpatient departments participate in the 340B Drug Pricing Program, which requires manufacturers to sell covered outpatient drugs at a significant discount [15]. Patients who receive care at a 340B-covered entity may access liraglutide at substantially reduced cost regardless of insurance status. To find a 340B-covered pharmacy, the Health Resources and Services Administration (HRSA) maintains a public database at hrsa.gov.

Compounded Liraglutide: A Clear Warning

Some compounding pharmacies advertise "compounded liraglutide" at lower prices. The FDA has not approved any compounded version of liraglutide, and the agency has issued warning letters to compounders marketing these products [16]. Compounded liraglutide carries unknown potency, sterility risk, and no manufacturer pharmacovigilance. HealthRX does not prescribe or endorse compounded liraglutide.

Is There a Generic Liraglutide? What to Expect

No FDA-approved generic liraglutide exists as of January 2026. Liraglutide is a 31-amino-acid fatty-acid-acylated peptide, not a small molecule, so it does not qualify for standard generic approval under the Hatch-Waxman pathway. A biosimilar would require the 351(k) pathway under the Biologics Price Competition and Innovation Act (BPCIA) [17]. Novo Nordisk's core liraglutide patents began expiring in 2023, and several biosimilar developers have disclosed development programs, but none had received FDA approval by January 2026.

When a biosimilar liraglutide does reach the market, it will likely be designated "interchangeable" only if it passes additional switching studies. Medicaid PDLs would then need to be updated to add the biosimilar, potentially with preferred-tier placement if rebate negotiations favor it.

State-by-State Quick Reference Table

The table below summarizes coverage status for Victoza and Saxenda across the 20 most populous states as of January 2026. Because Medicaid PDLs update quarterly, always verify the current PDL at your state Medicaid agency website before submitting a PA.

| State | Victoza Coverage | Victoza PA Required | Saxenda Coverage | Saxenda PA Required | |---|---|---|---|---| | California (Medi-Cal) | Yes | Yes | Yes | Yes | | Texas | Yes | Yes (2-drug step) | No | N/A | | Florida | Yes | Yes (2-drug step) | No | N/A | | New York | Yes | Yes | Yes | Yes | | Pennsylvania | Yes | Yes | Yes (limited) | Yes | | Illinois | Yes | Yes | No | N/A | | Ohio | Yes | Yes | No | N/A | | Georgia | Yes | Yes (2-drug step) | No | N/A | | North Carolina | Yes | Yes | No | N/A | | Michigan | Yes | Yes | Yes | Yes | | New Jersey | Yes | Yes | Yes | Yes | | Virginia | Yes | Yes | No | N/A | | Washington | Yes | Yes | Yes | Yes | | Arizona | Yes | Yes | No | N/A | | Massachusetts | Yes | Yes | Yes | Yes | | Tennessee | Yes | Yes | No | N/A | | Indiana | Yes | Yes | No | N/A | | Missouri | Yes | Yes | No | N/A | | Maryland | Yes | Yes | No | N/A | | Colorado | Yes | Yes | Yes | Yes |

What the Clinical Evidence Says About Coverage Decisions

Medicaid coverage decisions are not made in a clinical vacuum. States reference published evidence and guideline statements when drafting PA criteria. Understanding the evidence base helps prescribers write more persuasive PA letters.

Cardiovascular Benefit (Victoza)

The LEADER trial remains the cornerstone citation for Victoza PA letters in patients with cardiovascular disease or high cardiovascular risk [6]. The FDA approved a cardiovascular risk reduction indication for Victoza in August 2017 based on LEADER data, and this indication is explicitly referenced in the ADA's 2024 Standards of Care as supporting GLP-1 use independent of glycemic status [7]. A PA letter for a patient with established atherosclerotic cardiovascular disease should lead with the cardiovascular indication, not the glycemic indication, because the cardiovascular argument is harder for a state reviewer to deny.

Weight Loss Benefit (Saxenda)

The SCALE Maintenance trial (N=422) showed that patients who had already lost at least 5% of body weight on liraglutide 3.0 mg and continued therapy maintained significantly more weight loss than those switched to placebo at one year (mean difference 6.2 percentage points, P<0.001) [18]. This trial supports the argument that discontinuing Saxenda after initial response causes clinically significant weight regain, which can be framed in a PA renewal letter to justify continued coverage.

Pediatric Data

The FDA approved Saxenda for adolescents aged 12 to 17 with obesity in December 2020. The SCALE Teens trial (N=251) showed liraglutide 3.0 mg reduced BMI by 4.64% relative to placebo at 56 weeks (P<0.001) [19]. Several state Medicaid programs extended Saxenda coverage to this age group following FDA approval, but PA criteria for pediatric patients typically require documentation from a pediatric endocrinologist or obesity medicine specialist.

How HealthRX Supports Patients Through the Coverage Process

HealthRX clinicians document prior authorization requests using structured templates that address each state's specific PA criteria. For patients in states that do not cover Saxenda, the clinical team reviews whether the patient qualifies for the Novo Nordisk Patient Assistance Program or a 340B-covered pharmacy, and whether switching to a covered GLP-1 (such as semaglutide, which has broader Medicaid coverage in some states) is clinically appropriate.

Patients prescribed liraglutide through HealthRX receive a detailed cost estimate before the prescription is sent. If the estimated out-of-pocket cost exceeds $150 per month, the care coordinator initiates a PA automatically and contacts the patient's state Medicaid plan within one business day.